Publications by authors named "N A Mohile"
Background: Pelvic fractures often result in traumatic and intraoperative blood loss. Cell salvage (CS) is a tool where autologous blood lost during surgery is collected and recycled with anticoagulation, centrifugation to separate red blood cells, and washing to be reinfused back to the patient. The purpose of this study was to investigate our experience with CS in pelvic and acetabular surgery and its relationship to perioperative transfusion requirements.
View Article and Find Full Text PDFWe report the efficacy of trastuzumab deruxtecan (T-DXd) in treating human epidermal growth factor receptor 2 (HER2) low, type ID leptomeningeal breast cancer (LMD) (with positive cerebrospinal fluid [CSF] cytology and hydrocephalus as the only abnormal imaging finding) and the diagnostic and monitoring utilization of a novel microfluidic platform called CNSide™. Breast cancer LMD is associated with poor prognosis, and effective treatments are lacking. Our case highlights two crucial aspects related to the treatment and monitoring of breast cancer LMD.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the connection between breast cancer subtypes and CSF cytology results with overall survival among patients with leptomeningeal disease.
- Out of 69 participants, triple-negative breast cancer was linked to significantly shorter survival compared to ER+/HER2- subtype, while CSF- patients had better overall survival compared to those with positive or not tested CSF results.
- The findings highlight the importance of breast cancer subtypes and CSF cytology in determining patient prognosis, suggesting that specific subtypes could influence survival outcomes.
Article Synopsis
- Glioblastoma patients typically have a poor prognosis even after standard treatments, prompting research into new combinations of therapy.
- The study evaluated the effectiveness of veliparib combined with temozolomide for glioblastoma patients with MGMT promoter hypermethylation, hoping to enhance treatment outcomes.
- Results showed a slight improvement in median overall survival for the veliparib group compared to the placebo, but the difference wasn't significant enough to meet efficacy goals, though the combination treatment was generally well tolerated.